Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
COMy 2022
Watch our interview from #ASH25 with Lynette Chee of @PeterMacCC to hear updated results from an ongoing Phase II trial of elritercept in patients with transfusion-dependent LR-MDS.🩸
Click here: 👉
#MDSsm #CTSM #TrialUpdate #HemOnc
Updated results from a Phase II trial of elritercept in LR-MDS
Lynette Chee, MBBS, PhD, The Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Melbourne, Australia, shares updated ...
ow.ly
Our latest podcast dives into key multiple myeloma updates from #ASH25 🩸
From redefining functional high-risk disease to CAR-T and T-cell engagers.
🎧 Listen here:
Featuring Luciano Costa (@End_myeloma), Nisha Joseph (@nishjo76), Shambavi Richard,
Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T,...
This podcast features key updates in multiple myeloma from ASH 2025. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham,...
ow.ly
Could progression of disease within 36 months (POD36) of starting first-line targeted therapy be used as a clinical tool to identify high-risk patients with CLL?🩸
@hampel_p of @MayoClinic provides insight into this in a video interview from #ASH25:
🎥
POD36 as a prognostic marker and clinical tool in frontline CLL
In this interview, Paul Hampel, MD, Mayo Clinic, Rochester, MN, highlights that progression of disease within 36 mon...
ow.ly
We recently interviewed @michaelwangmd of @MDAndersonNews to hear the results of the Phase I/II trial investigating sonrotoclax monotherapy in patients with R/R #MantleCellLymphoma who had previously been treated with a BTKi.
Click here to watch: 👉
Sonrotoclax monotherapy in R/R MCL previously treated with a BTKi: early Phase I/II results
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the early results of th...
ow.ly
We are thrilled to once again be the official media partner for the annual EBMT-EHA European CAR T-cell Meeting, which will take place in Palma de Mallorca, Spain, from 12–14 February! 🇪🇸
Want to join us there or attend virtually?
Register here:
👉 https://ow.ly/4WLv50XT1IT..
COMy 2022
Watch our interview from #ASH25 with Lynette Chee of @PeterMacCC to hear updated results from an ongoing Phase II trial of elritercept in patients with transfusion-dependent LR-MDS.🩸
Click here: 👉
#MDSsm #CTSM #TrialUpdate #HemOnc
Updated results from a Phase II trial of elritercept in LR-MDS
Lynette Chee, MBBS, PhD, The Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Melbourne, Australia, shares updated ...
ow.ly
Our latest podcast dives into key multiple myeloma updates from #ASH25 🩸
From redefining functional high-risk disease to CAR-T and T-cell engagers.
🎧 Listen here:
Featuring Luciano Costa (@End_myeloma), Nisha Joseph (@nishjo76), Shambavi Richard,
Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T,...
This podcast features key updates in multiple myeloma from ASH 2025. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham,...
ow.ly
Could progression of disease within 36 months (POD36) of starting first-line targeted therapy be used as a clinical tool to identify high-risk patients with CLL?🩸
@hampel_p of @MayoClinic provides insight into this in a video interview from #ASH25:
🎥
POD36 as a prognostic marker and clinical tool in frontline CLL
In this interview, Paul Hampel, MD, Mayo Clinic, Rochester, MN, highlights that progression of disease within 36 mon...
ow.ly
We recently interviewed @michaelwangmd of @MDAndersonNews to hear the results of the Phase I/II trial investigating sonrotoclax monotherapy in patients with R/R #MantleCellLymphoma who had previously been treated with a BTKi.
Click here to watch: 👉
Sonrotoclax monotherapy in R/R MCL previously treated with a BTKi: early Phase I/II results
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the early results of th...
ow.ly
We are thrilled to once again be the official media partner for the annual EBMT-EHA European CAR T-cell Meeting, which will take place in Palma de Mallorca, Spain, from 12–14 February! 🇪🇸
Want to join us there or attend virtually?
Register here:
👉 https://ow.ly/4WLv50XT1IT..
